Amendments to the Claims

Claims 1-49. (Canceled)

Claim 50. (New) An expression vector comprising, in the following order, a promoter sequence, a first coding sequence, a polyadenylation site, and a second coding sequence operably linked to the first coding sequence, wherein no promoter sequence occurs between the polyadenylation site and the second coding sequence, and wherein the first coding sequence or the second coding sequence encodes a recombinant protein selected from the group consisting of an immunoglobulin molecule, a TNF alpha receptor, an Interleukin-1 receptor, an Interleukin-4 receptor, an Interleukin-15 receptor, an Interleukin-17 receptor, an Interleukin-18 receptor, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, leukemia inhibitory factor receptor, receptor activator of NF-kappa B (RANK), a TRAIL receptor, Fas, Apoptosis-Inducing Receptor (AIR), brain-derived neurotrophic factor, ciliary neurotrophic factor, glial cell-line derived neurotrophic factor, flt-3 ligand, TNF-related apoptosis-inducing ligand (TRAIL), CD40 ligand, Ox40 ligand, 4-1BB ligand, thymic stroma-derived lymphopoietin, mast cell growth factor, stem cell growth factor, epidermal growth factor, growth hormone, tumor necrosis factor, leukemia inhibitory factor, oncostatin-M, an erythropoietin, thrombopoietin, streptokinase and tissue plasminogen activator.

Claim 51. (New) The expression vector of claim 50, wherein the second coding sequence encodes a selectable marker.

Claim 52. (New) The expression vector of claim 51, wherein the selectable marker is dihydrofolate reductase.

Claim 53. (New) The expression vector of claim 50 wherein the polyadenylation site comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and residues 80 through 222 of SEQ ID NO:1.

Claim 54. (New) The expression vector of claim 51 wherein the polyadenylation site comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and residues 80 through 222 of SEQ ID NO:1.

Claim 55. (New) The expression vector of claim 52 wherein the polyadenylation site comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and residues 80 through 222 of SEQ ID NO:1.

Claim 56. (New) The expression vector of claim 50 wherein an internal ribosome entry site (IRES) is inserted between the polyadenylation site and the second coding sequence such that the IRES is operably linked to the-second coding sequence.

Claim 57. (New) The expression vector of claim 51 wherein an internal ribosome entry site (IRES) is inserted between the polyadenylation site and the selectable marker such that the IRES is operably linked to the selectable marker.

Claim 58. (New) The expression vector of claim 52 wherein an internal ribosome entry site (IRES) is inserted between the polyadenylation site and the selectable marker such that the IRES is operably linked to the selectable marker.

Claim 59. (New) The expression vector of claim 53 wherein an internal ribosome entry site (IRES) is inserted between the polyadenylation site and the second coding sequence such that the IRES is operably linked to the second coding sequence.

Claim 60. (New) The expression vector of claim 54 wherein an internal ribosome entry site (IRES) is inserted between the polyadenylation site and the selectable marker such that the IRES is operably linked to the selectable marker.

Claim 61. (New) The expression vector of claim 55 wherein an internal ribosome entry site (IRES) is inserted between the polyadenylation site and the selectable marker such that the IRES is operably linked to the selectable marker.

Claim 62. (New) A mammalian cell stably transformed with the expression vector according to claim 50.

Claim 63. (New) A mammalian cell stably transformed with the expression vector according to claim 51.

Claim 64. (New) A mammalian cell stably transformed with the expression vector according to claim 56.

Claim 65. (New) A mammalian cell stably transformed with the expression vector according to claim 57.

Claim 66. (New) A mammalian cell stably transformed with the expression vector according to claim 59.

Claim 67. (New) A mammalian cell stably transformed with the expression vector according to claim 61.

Claim 68. (New) A method for obtaining a recombinant protein, comprising culturing a cell line according to claim 62 under conditions promoting expression of the protein, and recovering the protein.

Claim 69. (New) A method for obtaining a recombinant protein, comprising culturing a cell line according to claim 63 under conditions promoting expression of the protein, and recovering the protein.

Claim 70. (New) A method for obtaining a recombinant protein, comprising culturing a cell line according to claim 64 under conditions promoting expression of the protein, and recovering the protein.

Claim 71. (New) A method for obtaining a recombinant protein, comprising culturing a cell line according to claim 65 under conditions promoting expression of the protein, and recovering the protein.

Claim 72. (New) A method for obtaining a recombinant protein, comprising culturing a cell line according to claim 66 under conditions promoting expression of the protein, and recovering the protein.

Claim 73. (New) A method for obtaining a recombinant protein, comprising culturing a cell line according to claim 67 under conditions promoting expression of the protein, and recovering the protein.

Claim 74. (New) The expression vector of claim 50, which further comprises a second polyadenylation site following the second coding sequence and operably linked thereto.